Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology
Thermo Fisher Scientific (NYSE: TMO) is collaborating with the National Cancer Institute (NCI) to advance the myeloMATCH precision medicine clinical trial. This trial aims to accelerate research and treatment for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) using next-generation sequencing (NGS) technology. By quickly identifying genetic biomarkers in patients' bone marrow and blood, the trial aims to match patients to appropriate clinical studies. This approach could lead to more personalized and effective treatments, potentially increasing the survival rate for these aggressive cancers. The trial will deploy Thermo Fisher's Ion Torrent Genexus System, which offers next-day genomic testing and covers over 2,200 sites in North America.
- Thermo Fisher's NGS technology accelerates matching of AML and MDS patients to clinical trials.
- Partnership with NCI enhances credibility and scope of the myeloMATCH trial.
- Genexus System offers next-day genomic testing, expediting treatment initiation.
- myeloMATCH trial includes over 2,200 clinical sites across North America.
- High complexity and cost associated with next-generation sequencing technology.
- The trial relies heavily on rapid and accurate genetic profiling, which may not be accessible to all patients.
Insights
Thermo Fisher Scientific partnering on the myeloMATCH clinical trial is highly notable for oncology, particularly in the battle against Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). These diseases progress rapidly, with survival rates significantly impacted by the speed of detection and treatment. The utilization of next-generation sequencing (NGS) technology to identify genetic biomarkers in patients' bone marrow and blood is a game-changer. Rapid genomic profiling can facilitate personalized treatment plans, improving both the efficacy of interventions and patient outcomes.
This partnership enables a more tailored approach to treatment, which is essential given the genetic diversity found in AML and MDS. The development of the Ion Torrent Genexus System underscores the drive towards rapid, accurate and automated genomic testing, reducing the time to treatment initiation. In clinical practice, quicker identification of suitable clinical trials could mean the difference between life and death for patients with aggressive forms of leukemia.
By streamlining the process of matching patients to trials, the potential to increase survival rates is profound. This approach aligns well with current clinical guidelines emphasizing the need for quick and precise genetic analysis. However, the long-term effectiveness of these new targeted therapies still needs to be rigorously evaluated in diverse patient populations.
Thermo Fisher Scientific's involvement in the myeloMATCH clinical trial has significant financial implications. Partnering with the National Cancer Institute (NCI) demonstrates a strategic move to bolster its position in the precision medicine market, capitalizing on the increasing demand for genomic testing. The adoption of the Ion Torrent Genexus System to accelerate patient enrollment in trials could potentially lead to increased revenue streams from both the sale of the system and associated consumables.
This collaboration also enhances Thermo Fisher's reputation and credibility in the life sciences sector. By addressing a critical need for faster genetic testing in oncology, Thermo Fisher positions itself as a pivotal player in precision medicine. The trial's success could lead to broader commercial applications of the Genexus System, amplifying its growth prospects.
Short-term, investors might see a spike in stock value driven by positive market sentiment and increased visibility. However, long-term sustainability will hinge on the outcomes of these clinical trials and subsequent FDA approvals for diagnostic use. Potential risks include the high costs associated with R&D and the inherent uncertainties in clinical trial outcomes.
The myeloMATCH trial underscores a growing trend in the precision medicine market, which seeks to tailor medical treatment to individual genetic profiles. This initiative is a strong indicator of the industry's shift towards more personalized healthcare solutions. For investors, understanding this trend is important as it reflects a broader market evolution towards technologies that enable rapid, precise and personalized treatment options.
The trial's focus on AML and MDS, conditions with high unmet medical needs, highlights an opportunity to tap into a market seeking more effective and timely treatments. Successful implementation and positive trial results could drive demand for NGS technologies beyond oncology, expanding into other medical fields.
Moreover, the cooperation with multiple pharmaceutical companies and the use of diverse drugs indicate a collaborative approach that could lead to the development of a range of new treatments. This diversified strategy can mitigate risks associated with single-drug dependency and enhance the trial's overall success rate.
In summary, this initiative not only addresses immediate clinical needs but also positions Thermo Fisher and its Genexus System at the forefront of a transformative trend in healthcare, potentially leading to significant market opportunities.
myeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing to Quickly Match Patients with Appropriate Trials Across North America
myeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing to Quickly Match Patients with Appropriate Trials Across North America (Photo: Business Wire)
AML is an aggressive cancer of the bone marrow and blood and is one of the most common types of leukemia. Because it can advance quickly with a five-year survival rate of only 30
“myeloMATCH breaks new ground in many ways, not least by assembling a portfolio of sub-studies to treat patients with specific subtypes of AML and MDS through all stages of their treatment journey,” said Dr. Harry P. Erba, chair of the Southwest Oncology Group (SWOG) Leukemia Committee and co-chair of the myeloMATCH Senior Science Council. “Many more treatment options are available for people with AML and MDS than just 5-10 years ago, and many more targeted therapies are being developed. However, to choose the best treatment option for our patients requires knowledge of the genetic changes that underly the disease, which vary between patients. This information is needed quickly in order to begin effective therapy for very aggressive cancers. Our partnership with Thermo Fisher allows us to obtain the required genomic profiling rapidly and begin therapies specific for each subtype of the disease. Through this personalized approach to treatment, we believe we will increase the number of people who are leukemia survivors."
The study aims to complete genomic testing and deliver complete results within a few days across testing modalities to help quickly enroll patients into specific sub-studies based on their biomarker profile at time of diagnosis. As the first turnkey NGS solution that automates the specimen-to-report workflow designed to deliver results in a single day with just two user touchpoints, the Ion Torrent™ Genexus™ System* will help accelerate the process of matching patients with appropriate clinical trials.
myeloMATCH will be open in the
“myeloMATCH is an immense step forward for patients with aggressive and rapidly advancing cancers who need better treatment options,” said John Sos, senior vice president and president, life sciences solutions at Thermo Fisher Scientific. “Using the Genexus System, clinical teams across sites can quickly match eligible patients with the right trials to ultimately better understand the clinical impact of these therapies. By helping to expedite this process, we can ensure that more patients have access to appropriate precision oncology treatments.”
Patient samples will be sequenced in the myeloMATCH Molecular Diagnostics Laboratory Network (MDNet) using the Genexus System and reagents along with the Oncomine-based NCI Myeloid Assay as part of an approved Investigational Device Exemption (IDE) to assign participants to myeloMATCH treatment studies and has received Investigational New Drug authorization by the
To learn more about myeloMATCH, please visit https://clinicaltrials.gov/study/NCT05564390
* Available for research use only in
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711570854/en/
Media Contact Information:
Sandy Pound
Thermo Fisher Scientific
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information
Rafael Tejada
Thermo Fisher Scientific
Phone: 781-622-1256
Email: rafael.tejada@thermofisher.com
Source: Thermo Fisher Scientific Inc.
FAQ
What is the myeloMATCH precision medicine clinical trial?
How does Thermo Fisher's technology contribute to the myeloMATCH trial?
What is the expected impact of the myeloMATCH trial on AML and MDS treatments?
How many sites are involved in the myeloMATCH trial?
What specific technology is being used in the myeloMATCH trial?
